together withcharles_river_logo

Patient-derived xenograft (PDX) mouse models allow propagation and characterization of valuable primary tumor material and subsequent compound testing. To expand the potential of these human-relevant PDX models, OcellO offers in vitro assays using 3D cultures of the same tumor material. OcellO’s high content imaging and analysis platform enables in-depth evaluation of drug effects in a robust high throughput format.

 

OcellO’s in vitro PDX assays enable:

– pre-selection of lead compounds in cultured human tissues

– discrimination of compound activity, selectivity and cytotoxicity

– pre-selection of the optimum PDX tumor models from the Charles River Laboratories PDX collection for follow-up in vivo studies

– direct link between in vitro and in vivo using the same PDX model

– reduced timelines, attrition, costs and amount of test compound needed

 

MAXF 2499 MAXF 1322 MAXF 1162 CXF 1753 CXF 2049
MAXF 2499 MAXF 1322 MAXF 1162 CXF 1753 CXF 2049

 

PAXF 1657

Pancreatic cancer in vitro PDX model

Technology highlights:

in vitro culture of PDX tumor for direct translation to in vivo

• Automated high content compound evaluation in 384-well plate format

• Sensitive and robust measurement of clinically-relevant end-points

 

 

Choose from >350 well-characterized tumor PDX models

Lung Gastric Bladder Breast Colon Pancreas
90+ 30+ 10 15 60+ 40+
Lung cancer 1 Gastric cancer 2 Bladder cancer 1 Breast cancer 2 Colon cancer 1 Pancreas cancer 1

 

3D image-based quantification of compound responses

9 point dose response curve of small molecules tested in a breast cancer in vitro PDX model

9 point dose response curve of small molecules tested in a breast cancer in vitro PDX model

 

For testing antibodies, antibody-drug-conjugates, small molecules and more

 

For more information, download the in vitro PDX flyer or contact us.

For more information on the Charles River Laboratories PDX collection visit the CR website here or contact holly.collette@crl.com